CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; SITAGLIPTIN
✉ Email this page to a colleague
All Clinical Trials for METFORMIN HYDROCHLORIDE; SITAGLIPTIN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00103857 ↗ | MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-03-17 | The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes). |
NCT00337610 ↗ | Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-01 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy. |
NCT00350779 ↗ | Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-12 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy. |
NCT00395343 ↗ | Sitagliptin Added-on to Insulin Study (0431-051) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-12-11 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy. |
NCT00420511 ↗ | Beta-Cell Function and Sitagliptin Trial (BEST) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2007-01-01 | Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a double-blind, randomized controlled pilot study comparing the effect of sitagliptin (a novel anti-diabetic drug with beta-cell protective potential) versus placebo, on the preservation of beta-cell function over one year in patients with T2DM on metformin, the first-line agent for the treatment of T2DM (ie. the study groups will be (i) sitagliptin and metformin versus (ii) placebo and metformin). This study may demonstrate an important beta-cell protective capacity of sitagliptin. Hypothesis: In patients with T2DM on metformin, treatment with the DPP-IV inhibitor sitagliptin will preserve pancreatic beta-cell function. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METFORMIN HYDROCHLORIDE; SITAGLIPTIN
Condition Name
Clinical Trial Locations for METFORMIN HYDROCHLORIDE; SITAGLIPTIN
Trials by Country
Clinical Trial Progress for METFORMIN HYDROCHLORIDE; SITAGLIPTIN
Clinical Trial Phase
Clinical Trial Sponsors for METFORMIN HYDROCHLORIDE; SITAGLIPTIN
Sponsor Name